Trial Profile
RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Acronyms RADVAX
- 08 Jun 2021 Final Results assessing toxicity and objective response to HFRT + pembrolizumab, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 13 Apr 2020 Status changed from active, no longer recruiting to completed.
- 22 Apr 2019 Status changed from recruiting to active, no longer recruiting.